-
1دورية أكاديمية
المؤلفون: Rasco, Drew W, Medina, Theresa, Corrie, Pippa, Pavlick, Anna C, Middleton, Mark R, Lorigan, Paul, Hebert, Chris, Plummer, Ruth, Larkin, James, Agarwala, Sanjiv S, Daud, Adil I, Qiu, Jiaheng, Bozon, Viviana, Kneissl, Michelle, Barry, Elly, Olszanski, Anthony J
المصدر: Cancer chemotherapy and pharmacology. 92(1)
مصطلحات موضوعية: Humans, Neoplasms, Melanoma, Skin Neoplasms, Neoplasms, Second Primary, Proto-Oncogene Proteins B-raf, Mitogen-Activated Protein Kinase Kinases, Protein Kinase Inhibitors, Maximum Tolerated Dose, Adult, BRAF, Pan-RAF inhibitor, Phase 1, Tovorafenib, Clinical Trials and Supportive Activities, Clinical Research, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Pharmacology and Pharmaceutical Sciences, Oncology & Carcinogenesis
وصف الملف: application/pdf
الوصول الحر: https://escholarship.org/uc/item/6jq463hgTest
-
2دورية أكاديمية
المؤلفون: Rasco, DW, Medina, T, Corrie, P, Pavlick, AC, Middleton, MR, Lorigan, P, Hebert, C, Plummer, R, Larkin, J, Agarwala, SS, Daud, AI, Qiu, J, Bozon, V, Kneissl, M, Barry, E, Olszanski, AJ
المساهمون: Larkin, James
مصطلحات موضوعية: BRAF, Melanoma, Pan-RAF inhibitor, Phase 1, Tovorafenib, Adult, Humans, Proto-Oncogene Proteins B-raf, Neoplasms, Skin Neoplasms, Protein Kinase Inhibitors, Second Primary, Mitogen-Activated Protein Kinase Kinases, Maximum Tolerated Dose
جغرافية الموضوع: Germany
وصف الملف: Print-Electronic; 28; application/pdf
العلاقة: Cancer Chemotherapy and Pharmacology, 2023, 92 (1), pp. 15 - 28; https://repository.icr.ac.uk/handle/internal/5936Test
الإتاحة: https://doi.org/10.1007/s00280-023-04544-5Test
https://repository.icr.ac.uk/handle/internal/5936Test